SM
ALXN

SG3 Management’s Alexion Pharmaceuticals ALXN Stock Holding History

SG3 Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,000
Closed -$551K – 1765
2021
Q2 		$551K Buy
3,000
+1,500
+100% +$257K 0.23% 637
2021
Q1 		$229K Sell
1,500
-28,800
-95% -$4.45M 0.07% 938
2020
Q4 		$4.73M Buy
+30,300
New +$3.89M 0.7% 210
2020
Q3 		– Sell
-9,000
Closed -$971K – 1456
2020
Q2 		$1.01M Buy
+9,000
New +$956K 0.65% 286
2020
Q1 		– Hold
0
– – – 636
2019
Q4 		– Hold
0
– – – 541
2019
Q3 		– Hold
0
– – – 707
2019
Q2 		– Hold
0
– – – 786

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return